<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-3466</journal-id>
<journal-title><![CDATA[Revista Cubana de Salud Pública]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cub Sal Públ]]></abbrev-journal-title>
<issn>0864-3466</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-34662025000100004</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eficacia y seguridad en la vacuna meningocócica tetravalente]]></article-title>
<article-title xml:lang="en"><![CDATA[Efficacy and Safety of the Tetravalent Meningococcal Vaccine]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escandell Rico]]></surname>
<given-names><![CDATA[Francisco Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Fernández]]></surname>
<given-names><![CDATA[Lucia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Alicante  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>51</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-34662025000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-34662025000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-34662025000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La enfermedad meningocócica invasiva es una infección bacteriana aguda grave, en la gran mayoría de los casos es causada por cinco serogrupos de Neisseriameningitidis (A, B, C, W, Y). La carga de la enfermedad y las altas tasas de mortalidad resaltan la necesidad de la prevención a través de una inmunización activa eficaz y segura.  Objetivo: Describir la eficacia y seguridad en la vacuna meningocócica tetravalente.  Métodos:  Estudio de revisión sistemática. Se siguieron las propuestas para mejorar la publicación de revisiones sistemáticas PRISMAScR. Se incluyeron todos los artículos disponibles en inglés, publicados en revistas académicas revisadas por pares y publicados entre 2017 y 2022. Se excluyeron los artículos que describían la eficacia y seguridad en otras vacunas que no fueran meningocócica tetravalente.  Resultados:  Después de analizar el contenido de los ocho artículos incluidos, se identificaron cuatro temas de la vacuna meningocócica ACWY: en bebés y niños pequeños, niños de 2 a 10 años, adolescentes y adultos, todas las edades. Con respecto a la seguridad, independientemente del rango de edad, se destaca el dolor en el lugar de la inyección como una de las notificaciones de registros de efectos adversos más frecuentes. En relación con la eficacia, los artículos analizados se centranen la persistencia de anticuerpos en el tiempo en relación con las dosis/edad.  Conclusiones:  Existe una clara necesidad de seguir desarrollando herramientas estandarizadas sobre la eficacia y seguridad en la vacuna meningocócica tetravalente, ya que a nivel internacional hay diferentes estrategias vacunales, presentaciones y respuestas inmunitarias.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Invasive meningococcal disease (IMD) is a severe acute bacterial infection, and in the vast majority of cases is caused by five serogroups of Neisseriameningitidis (A, B, C, W, Y). The burden of disease and high mortality rates highlight the need for prevention through effective and safe active immunization.  Objective:  Describe the efficacy and safety of the quadrivalent meningococcal vaccine.  Methods: This is a systematic review study. The proposals to improve the publication of PRISMAScR systematic reviews were followed. All articles available in English, published in peer-reviewed academic journals, and published between 2017 and 2022 were included. Articles describing the efficacy and safety of vaccines other than quadrivalent meningococcal vaccines were excluded.  Results: After content analysis of the 8 included articles, four ACWY meningococcal vaccine themes were identified: infants and toddlers, children 2-10 years, adolescents, and adults, all ages. Regarding safety, regardless of age range, we highlight injection site pain as one of the most common adverse effect registry reports. In relation to efficacy, the articles analyzed focus on the persistence of antibodies over time in relation to doses/age.  Conclusions: There is a clear need to develop effective and safe standardized tools in the meningococcal vaccine, since at the international level there are different vaccine strategies, presentations and immune responses.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[tetravalente]]></kwd>
<kwd lng="es"><![CDATA[meningocócica]]></kwd>
<kwd lng="es"><![CDATA[vacuna]]></kwd>
<kwd lng="es"><![CDATA[eficacia]]></kwd>
<kwd lng="es"><![CDATA[seguridad]]></kwd>
<kwd lng="en"><![CDATA[tetravalent]]></kwd>
<kwd lng="en"><![CDATA[meningococcal]]></kwd>
<kwd lng="en"><![CDATA[vaccine]]></kwd>
<kwd lng="en"><![CDATA[efficacy]]></kwd>
<kwd lng="en"><![CDATA[safety]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Centros para el Control y la Prevención de Enfermedades</collab>
<source><![CDATA[Epidemiología y Prevención de Enfermedades Prevenibles por Vacunación]]></source>
<year>2015</year>
<edition>13</edition>
<publisher-loc><![CDATA[Washington, DC ]]></publisher-loc>
<publisher-name><![CDATA[Fundación de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halperin]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Bettinger]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Greenwood]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Jelfs]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ladhani]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The changing and dynamic epidemiology of meningococcal disease]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2012</year>
<volume>30</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>B26-36</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud (OMS)</collab>
<source><![CDATA[Meningitis meningocócica - Hoja informativa]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Ginebra, Suiza ]]></publisher-loc>
<publisher-name><![CDATA[Organización Mundial de la Salud (OMS)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olbrich]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schumacher]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Meszaros]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Koerber]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic Review of Invasive Meningococcal Disease Sequelae and Quality of Life Impact on Patients and Their Caregivers]]></article-title>
<source><![CDATA[Infect Dis Ther]]></source>
<year>2018</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>421-38</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pelton]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines]]></article-title>
<source><![CDATA[J Adolesc Health. Aug]]></source>
<year>2016</year>
<volume>59</volume>
<numero>2^sSuppl</numero>
<issue>2^sSuppl</issue>
<supplement>Suppl</supplement>
<page-range>S3-S11</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Pelton]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Wilder-Smith]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Holst]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Safadi]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Global Meningococcal Initiative recommendations for reducing the global burden of meningococcal disease]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2011</year>
<volume>29</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>3363-71</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Sharyan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[SheikhiMoghaddam]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MeningococcalVaccines CurrentStatus and EmergingStrategies]]></article-title>
<source><![CDATA[Vaccines (Basel)]]></source>
<year>2018</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Auckland]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Borrow]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Goldblatt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsay]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2006</year>
<volume>194</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1745-52</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Borrow]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Salisbury]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meningococcal C conjugate vaccine the experience in England and Wales]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2009</year>
<volume>27</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>B20-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piazza]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Virta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paassilta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ukkonen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ahonen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Esteves-Jaramillo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers A Phase III, open-label, multi-center study]]></article-title>
<source><![CDATA[Hum VaccinImmunother]]></source>
<year>2022</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hedrick]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jordanov]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dhingra]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2020</year>
<volume>38</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>3560-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhingra]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hedrick]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Neveu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jordanov]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity, safety and inter-lotconsistencyof a meningococcalconjugatevaccine (MenACYW-TT) in adolescents and adults A Phase III randomizedstudy]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2020</year>
<volume>38</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>5194-201</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urrútia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bonfill]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Declaración PRISMA una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis [PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2010</year>
<volume>135</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>507-11</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tricco]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Lillie]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Zarin]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[O&amp;apos;Brien]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Colquhoun]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Levac]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PRISMA Extension for Scoping Reviews (PRISMA-ScR) Checklist and Explanation]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2018</year>
<volume>169</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>467-73</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
<name>
<surname><![CDATA[Shannon]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Three approaches to qualitative content analysis]]></article-title>
<source><![CDATA[Qual Health Res]]></source>
<year>2005</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1277-88</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Gøtzsche]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Jüni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Oxman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Cochrane Collaboration&amp;apos;s tool for assessing risk of bias in randomised trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2011</year>
<volume>343</volume>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoo]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Byeon]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
<name>
<surname><![CDATA[Curina]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months-55 years]]></article-title>
<source><![CDATA[Hum VaccinImmunother]]></source>
<year>2020</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1260-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Becerra-Culqui]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Sy]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerson]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Slezak]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fischetti]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2020</year>
<volume>38</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>228-34</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jo]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Persistencia de anticuerpos de un año y seguridad de un programa de 4 dosis de MenACWY-CRM en lactantes sanos de Corea del Sur]]></article-title>
<source><![CDATA[Clin Exp Vacuna Res]]></source>
<year>2019</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>94-102</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Pandit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Antin]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation]]></article-title>
<source><![CDATA[Blood Adv]]></source>
<year>2018</year>
<volume>2</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1272-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Myers]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[McNeil]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Cano]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo(r)) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2017</year>
<volume>35</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1758-63</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vandermeulen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Leroux-Roels]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vandeleur]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Staniscia]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Girard]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new fully liquid presentation of MenACWY-CRM conjugate vaccine Results from a multicentre, randomised, controlled, observer-blind study]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2021</year>
<volume>39</volume>
<numero>45</numero>
<issue>45</issue>
<page-range>6628-36</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Block]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Essink]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Barbi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Smolenov]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Keshavan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2019</year>
<volume>37</volume>
<numero>32</numero>
<issue>32</issue>
<page-range>4460-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Knol]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[ERA]]></given-names>
</name>
<name>
<surname><![CDATA[Bogaard]]></surname>
<given-names><![CDATA[MJM]]></given-names>
</name>
<name>
<surname><![CDATA[van Rooijen]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[EAM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands Two consecutive surveys in 2016/17 and 2020]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2022</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-66</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olbrich]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schumacher]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Meszaros]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Koerber]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic Review of Invasive Meningococcal Disease Sequelae and Quality of Life Impact on Patients and Their Caregivers]]></article-title>
<source><![CDATA[Infect Dis Ther]]></source>
<year>2018</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>421-38</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pelton]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines]]></article-title>
<source><![CDATA[J Adolesc Health]]></source>
<year>2016</year>
<volume>59</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>3-11</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keshavan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pellegrini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vadivelu-Pechai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nissen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine]]></article-title>
<source><![CDATA[Expert Rev Vaccines]]></source>
<year>2018</year>
<volume>17</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>865-80</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
